Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds?
Key takeaways
- Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds?
- EBGLYSS was already approved for once-monthly maintenance dosing, and the new option gives patients as few as six maintenance injections per year.
- That update followed a wave of diabetes and obesity data presented at the ADA 86th Scientific Sessions.
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? Faheem Tahir Sun, June 14, 2026 at 12:59 AM GMT+7 2 min read LLY With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock. That outlook comes during a particularly active stretch of regulatory and clinical news for Lilly’s drug pipeline.
On June 9, 2026, the FDA approved a new maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing a single 250 mg injection every eight weeks for adults and children 12 and older weighing at least 88 pounds with moderate-to-severe atopic dermatitis. EBGLYSS was already approved for once-monthly maintenance dosing, and the new option gives patients as few as six maintenance injections per year.
That update followed a wave of diabetes and obesity data presented at the ADA 86th Scientific Sessions.